NEDD4 degrades TUSC2 to promote glioblastoma progression
Copyright © 2022 Elsevier B.V. All rights reserved..
Whether tumor suppressor candidate 2 (TUSC2) plays an important role in glioblastoma (GBM) progression is largely unknown. Whether TUSC2 undergoes polyubiquitination is unknown. Herein, we report that TUSC2 protein expression is reduced/lost in GBM compared to normal brain due to protein destabilization; TUSC2 mRNA is equally expressed in both tissues. NEDD4 E3 ubiquitin ligase polyubiquitinates TUSC2 at residue K71, and the TUSC2-K71R mutant is resistant to NEDD4-mediated proteasomal degradation. Analysis of GBM specimens showed NEDD4 protein is highly expressed in GBM and the level is inversely correlated with TUSC2 protein levels. Furthermore, TUSC2 restoration induces apoptosis and inhibits patient-derived glioma stem cells (PD-GSCs) in vitro and in vivo. Conversely, TUSC2-knockout promotes PD-GSCs in vitro and in vivo. RNA-Seq analysis and subsequent validations showed GBM cells with TUSC2-knockout expressed increased Bcl-xL and were more resistant to apoptosis induced by a Bcl-xL-specific BH3 mimetic. A TUSC2-knockout gene signature created from the RNA-seq data predicts poor patient survival. Together, these findings establish that NEDD4-mediated polyubiquitination is a novel mechanism for TUSC2 degradation in GBM and that TUSC2 loss promotes GBM progression in part through Bcl-xL upregulation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:531 |
|---|---|
| Enthalten in: |
Cancer letters - 531(2022) vom: 10. Apr., Seite 124-135 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rimkus, Tadas K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Glioblastoma |
|---|
| Anmerkungen: |
Date Completed 22.04.2022 Date Revised 11.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canlet.2022.01.029 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336999364 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336999364 | ||
| 003 | DE-627 | ||
| 005 | 20231225233422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2022.01.029 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1123.xml |
| 035 | |a (DE-627)NLM336999364 | ||
| 035 | |a (NLM)35167936 | ||
| 035 | |a (PII)S0304-3835(22)00045-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rimkus, Tadas K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NEDD4 degrades TUSC2 to promote glioblastoma progression |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.04.2022 | ||
| 500 | |a Date Revised 11.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a Whether tumor suppressor candidate 2 (TUSC2) plays an important role in glioblastoma (GBM) progression is largely unknown. Whether TUSC2 undergoes polyubiquitination is unknown. Herein, we report that TUSC2 protein expression is reduced/lost in GBM compared to normal brain due to protein destabilization; TUSC2 mRNA is equally expressed in both tissues. NEDD4 E3 ubiquitin ligase polyubiquitinates TUSC2 at residue K71, and the TUSC2-K71R mutant is resistant to NEDD4-mediated proteasomal degradation. Analysis of GBM specimens showed NEDD4 protein is highly expressed in GBM and the level is inversely correlated with TUSC2 protein levels. Furthermore, TUSC2 restoration induces apoptosis and inhibits patient-derived glioma stem cells (PD-GSCs) in vitro and in vivo. Conversely, TUSC2-knockout promotes PD-GSCs in vitro and in vivo. RNA-Seq analysis and subsequent validations showed GBM cells with TUSC2-knockout expressed increased Bcl-xL and were more resistant to apoptosis induced by a Bcl-xL-specific BH3 mimetic. A TUSC2-knockout gene signature created from the RNA-seq data predicts poor patient survival. Together, these findings establish that NEDD4-mediated polyubiquitination is a novel mechanism for TUSC2 degradation in GBM and that TUSC2 loss promotes GBM progression in part through Bcl-xL upregulation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Glioblastoma | |
| 650 | 4 | |a Glioma stem cells | |
| 650 | 4 | |a NEDD4 | |
| 650 | 4 | |a TUSC2 | |
| 650 | 4 | |a Tumor suppressor | |
| 650 | 7 | |a TUSC2 protein, human |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Proteins |2 NLM | |
| 700 | 1 | |a Arrigo, Austin B |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Dongqin |e verfasserin |4 aut | |
| 700 | 1 | |a Carpenter, Richard L |e verfasserin |4 aut | |
| 700 | 1 | |a Sirkisoon, Sherona |e verfasserin |4 aut | |
| 700 | 1 | |a Doheny, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Regua, Angelina T |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Grace L |e verfasserin |4 aut | |
| 700 | 1 | |a Manore, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Calvin |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Hui-Kuan |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Guangxu |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz, Jimmy |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Debinski, Waldemar |e verfasserin |4 aut | |
| 700 | 1 | |a Lo, Hui-Wen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 531(2022) vom: 10. Apr., Seite 124-135 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
| 773 | 1 | 8 | |g volume:531 |g year:2022 |g day:10 |g month:04 |g pages:124-135 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2022.01.029 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 531 |j 2022 |b 10 |c 04 |h 124-135 | ||